Active Not RecruitingNCT05905003

AMP SCZ® Observational Study: PREDICT-DPACC

This study is active but not recruiting. It focuses on schizophrenia and currently lists study information in Australia, Canada, Chile, China, Denmark, Germany, Italy, Singapore, South Korea, Spain, Switzerland, the United Kingdom, and the United States.

SchizophreniaOtherFrom 12 Years to 30 Years

Need help deciding?

Ask HopeStage to review this study with me

Leave your email and HopeStage can help you better understand this study.

Study reference: NCT05905003. HopeStage can help you review the study, but cannot decide medical eligibility.

In plain English

Key information made simple

This observational study is following people with Clinical High Risk, Psychosis, Remission, or Conversion to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information. This study may not offer a new treatment, and its main value is helping researchers learn from follow-up information that may improve future care.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including University of California Irvine, University of California Los Angeles, and University of California San Diego. Participation appears to center on assessments, scans, or samples rather than trying a new treatment. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include other treatments that could interfere with the study and other factors that could make participation unsuitable. The official record does not list a trial phase, which usually means the study is focused on observation rather than testing a staged treatment.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Study clarity

Things to check before joining

Sponsor: Brigham and Women's Hospital
Sponsor type: Hospital / academic medical center
Main activity: observational follow-up
Intervention: Not available
Time commitment: long follow-up or multiple visits
Study phase: Not available
Enrollment: Not available
Recruitment status: Active Not Recruiting
Source: Official registry link

Public study data

Key study information

Official title: AMP SCZ® Observational Study: PREDICT-DPACC
Condition: Clinical High Risk; Psychosis; Remission; Conversion
Study status: Active Not Recruiting
Sponsor / lead affiliation: Brigham and Women's Hospital
Location / country: Australia, Canada, Chile, China, Denmark, Germany, Italy, Singapore, South Korea, Spain, Switzerland, United Kingdom, United States
Registry: ClinicalTrials.gov
External trial ID: NCT05905003

Why this study may matter

This study may matter because it adds public evidence around schizophrenia. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may help clarify how this condition is measured or understood.

It requires regular follow-up, often through questionnaires or interviews.

Requires travel, with in-person participation in Australia.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Official title: AMP SCZ® Observational Study: PREDICT-DPACC
Source: ClinicalTrials.gov
Official registry link: Open official registry
External trial ID: NCT05905003

Open source record

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is AMP SCZ® Observational Study: PREDICT-DPACC?

This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Brigham and Women's Hospital. Based on the sponsor name or official registry information, it appears to be a hospital or academic medical center. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve observational follow-up, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me